Study developed microencapsulated cholic acid to enhance antibacterial activity in livestock, suggesting potential for antibiotic-free production.
This study aimed to develop a microencapsulated cholic acid (CA) preparation to improve the stability, sustained-release performance, and antibacterial activity of CA for potential use in antibiotic-free animal production. CA microcapsules were prepared by complex coacervation using gelatin and gum arabic as wall materials, and the formulation was optimized by single-factor and orthogonal experimental designs. The optimal preparation conditions were a wall material concentration of 2.5%, a core-to-wall ratio of 1.8:1, and pH 4.1, yielding a drug loading rate of 49.73% and an encapsulation efficiency of 88.76%. The microcapsules showed spherical morphology, low hygroscopicity, improved thermal and storage stability, and a sustained-release profile over 72 h in simulated gastrointestinal media. Both free CA and microencapsulated CA significantly inhibited Escherichia coli growth ( p < 0.001), while the microcapsules provided a more prolonged antibacterial effect consistent with controlled release. These findings indicate that complex coacervation is a practical strategy for improving CA performance and support the potential use of CA microcapsules as antimicrobial feed additives in livestock production.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: